Edgar Filing: Kelly Scott A. - Form 4

Kelly Scott Form 4	А.										
November 1	ЛЛ							OMB A	PPROVAL		
	UNITED	STATES SECU Wa		AND EXCH 1, D.C. 2054		GE CO	OMMISSION	OMB Number:	3235-0287		
Check th if no lon subject to Section Form 4 of Form 5 obligation may com <i>See</i> Instra 1(b).	nger 16. or Dns tinue. Section 17(MENT OF CHAN rsuant to Section (a) of the Public U 30(h) of the I	NGES IN SECUI 16(a) of th Jtility Ho	BENEFIC RITIES he Securities lding Compa	IAL S Excl any A	hange Act of	Act of 1934, 1935 or Sectior	Expires: Estimated burden hou response	urs per		
(Print or Type	Responses)										
			2. Issuer Name and Ticker or Trading Symbol CytoDyn Inc. [CYDY]				5. Relationship of Reporting Person(s) to Issuer				
(Last)	•	of Earliest 7	-			(Check all applicable)					
1111 MAI	N STREET, SUIT		Day/Year) 2018				_X_ Director Officer (give below)		% Owner her (specify		
VANCOU	(Street) VER, WA 98660		endment, D onth/Day/Yea	Date Original ar)			6. Individual or Jo Applicable Line) _X_ Form filed by C Form filed by M	One Reporting P	erson		
(City)	(State)	(Zip) Tal	ale I - Non-	Dorivativa Sad	uritio		Person ired, Disposed of	or Bonoficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		3.	4. Securities A ondr Disposed of (Instr. 3, 4 an)	Acquin of (D)	-	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	11/16/2018		А	1,243,170	А	$\frac{(1)}{(2)}$	1,243,170	D			
Common Stock	11/16/2018		А	691,208	А	$\frac{(1)}{(2)}$	691,208	Ι	By Spouse		
Common Stock	11/16/2018		A	23,180	A	(<u>1</u>) (<u>2</u>)	23,180	I	As Custodian for Daughter; See Footnote (3)		
	11/16/2018		А	22,980	А		22,980	Ι			

Edgar Filing: Kelly Scott A. - Form 4

Common Stock			(<u>1)</u> (<u>2)</u>					As Custodian for Daughter; See Footnote (3)		
	Reminder: R	eport on a sep	arate line for each clas	ss of securities benefi	Person informa require	s who respond ation contained d to respond u s a currently va	to the collect in this form a nless the form	re not I	C 1474 (9-02)	
				ntive Securities Acqu outs, calls, warrants,						
	1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercis Expiration Dat (Month/Day/Y	e	7. Title and A Underlying S (Instr. 3 and	Securities
					Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
	Stock Options (right to buy)	\$ 0.61	11/16/2018		А	7,123	05/31/2017	04/10/2027	Common Stock	7,123
	Stock Options (right to buy)	\$ 0.57	11/16/2018		А	75,000	09/01/2018	06/01/2027	Common Stock	75,00
	Stock Options (right to buy)	\$ 0.56	11/16/2018		А	97,009	02/07/2018	02/07/2028	Common Stock	97,00
	Stock Options (right to buy)	\$ 0.49	11/16/2018		А	100,000	(4)	06/08/2028	Common Stock	100,00
	Stock Options (right to buy)	\$ 0.565	11/16/2018		А	250,000	11/08/2018	11/08/2028	Common Stock	250,00
		\$ 1.35	11/16/2018		А	50,000	05/26/2016	05/26/2021		50,00

Warrants (right to buy)							Common Stock	
Warrants (right to buy)	\$ 0.75	11/16/2018	А	166,666	02/10/2016	02/10/2021	Common Stock	166,66

Reporting Owners

Reporting Owner Name / Address

Relationships

10% Owner Officer Other

Director

Kelly Scott A. 1111 MAIN STREET, SUITE 660 X VANCOUVER, WA 98660

Signatures

/s/ Michael D. Mulholland, as attorney-in-fact

11/16/2018 Date

Explanation of Responses:

**Signature of Reporting Person

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company")

(1) Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock.

In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company
 (2) Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance).

- (3) The reporting person disclaims beneficial ownership of the reported securities, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
- (4) The options (including predecessor options) vest in four equal quarterly installments commencing on September 1, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.